Intratumoral and Combination Therapy in Melanoma and Other Skin Cancers
- 21 June 2019
- journal article
- review article
- Published by Springer Nature in American Journal of Clinical Dermatology
- Vol. 20 (6) , 781-796
Abstract
Skin cancer, as the most physically accessible malignancy, allows for the greatest variety in treatment innovation. The last 2 decades have seen striking increases in the life expectancies of those diagnosed with malignant melanoma. However, many cases remain in which disease prevails against standard treatment, and those patients rely on continuing ingenuity. Drugs that can be injected directly into patients’ tumors have become increasingly promising, not least for the reduction in side effects observed. Intratumoral therapy encompasses a wide array of agents, from chemotherapeutic drugs to cancer vaccines. While each show some efficacy, those agents which regulate the immune system likely have the greatest potential for preventing disease progression or recurrence. Recent research has highlighted the importance of the presence of cytotoxic T cells and of keeping regulatory T cells in check. Thus, manipulating the tumor microenvironment is a need in skin cancer therapy, which intratumoral delivery can potentially address. In order to find the best approach to each person’s disease, more studies are needed to test intralesional agents in combination with currently approved therapies and with each other.Keywords
This publication has 76 references indexed in Scilit:
- Combined TLR7/8 and TLR9 Ligands Potentiate the Activity of a Schistosoma japonicum DNA VaccinePLOS Neglected Tropical Diseases, 2013
- Tumor Infiltrating Immune Cells and Outcome of Merkel Cell Carcinoma: A Population-Based StudyClinical Cancer Research, 2012
- Electrochemotherapy for disseminated superficial metastases from malignant melanomaBritish Journal of Surgery, 2012
- The origin and development of nonlymphoid tissue CD103+ DCsJournal of Experimental Medicine, 2009
- Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic MelanomaJournal of Clinical Oncology, 2009
- Origin of the Lamina Propria Dendritic Cell NetworkImmunity, 2009
- Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2008
- Transdermal drug deliveryNature Biotechnology, 2008
- Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood, 2008
- Phase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanomaBritish Journal of Dermatology, 2007